



**STATE OF FLORIDA
DEPARTMENT OF HEALTH
INVESTIGATIVE SERVICES**

**Florida
HEALTH**

WWW.DOH.STATE.FL.US

NUCLEAR PHARMACY

File # 6825

ROUTINE CHANGE LOC NEW CURRENTLY NOT OPERATING CHANGE OWNER

Insp # 123200

INSPECTION AUTHORITY - CHAPTER 465.017, CHAPTER 893.09 AND CHAPTER 456, FLORIDA STATUTES

NAME OF ESTABLISHMENT ANAZOHEALTH CORP		PERMIT NUMBER 16308		DATE OF INSPECTION 12/5/2013								
DOING BUSINESS AS		DEA NUMBER		NUCLEAR PHARMICIST/MANAGER								
STREET ADDRESS 5710 HOOVER BLVD		TELEPHONE # (813) 882-4500		EXT. ARLINDA OANH CHAI								
CITY TAMPA		COUNTY 39		STATE/ZIP 33634								
LICENSE # 399												
PRESCRIPTION DEPARTMENT HOURS												
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday	REGISTERED PHARMACIST/INTERN/TECHNICIAN	LICENSE #			
Open	6:30	6:30	6:30	6:30	6:30	X	X	1. See attached				
Close	5	5	5	5	5			2.				
Satisfactory							Satisfactory					
YES NO							YES NO					
1	Current nuclear pharmacy permit. [465.0193, F.S.]						<input checked="" type="checkbox"/>	<input type="checkbox"/>	16	Pharmaceutical stock examined at least every four months and deteriorated or outdated items removed. [64B16-28.110, F.A.C.]	<input checked="" type="checkbox"/>	<input type="checkbox"/>
2	Licensed nuclear pharmacist in charge of pharmacy. [465.0193, F.S.]						<input checked="" type="checkbox"/>	<input type="checkbox"/>	17	In addition to other labeling requirements, the immediate outer container shield of the name of the radiopharmaceutical is labeled with standard radioactive symbol and words "Caution Radioactive Material," name of procedure, serial number, radionuclide and chemical form, amount of radioactivity and calibration date, the expiration date and time, the volume or weight, if a gas, the number of ampules or vials, molybdenum 99 content and the name of the patient or the words "Physicians use only." [64B16-28.901(9), F.A.C.]	<input checked="" type="checkbox"/>	<input type="checkbox"/>
3	Licensed nuclear pharmacist personally supervising all production. [64B16-28.901(1), F.A.C.]						<input checked="" type="checkbox"/>	<input type="checkbox"/>	18	The immediate inner container label of a radiopharmaceutical to be distributed has standard radiation symbol, "Caution Radioactive Material," radionuclide, chemical form, and the prescription number of the radiopharmaceutical. [64B16-28.901(10), F.A.C.]	<input checked="" type="checkbox"/>	<input type="checkbox"/>
4	Nuclear pharmacy area secured from access by unauthorized personnel. [64B16-28.901(2), F.A.C.]						<input checked="" type="checkbox"/>	<input type="checkbox"/>	19	Area for storage, compounding, distribution and disposal of radiopharmaceuticals is adequate to separate them from areas that contain non radioactive medicinal drugs. [64B16-28.902(1)(a), F.A.C.]	<input checked="" type="checkbox"/>	<input type="checkbox"/>
5	Each nuclear pharmacist maintains accurate records of the acquisition, inventory, distribution and disposal of all radiopharmaceuticals. [64B16-28.901(3), F.A.C.]						<input checked="" type="checkbox"/>	<input type="checkbox"/>	20	The hot lab storage area and compounding and dispensing area contain a minimum of 150 square feet. [64B16-28.902(1)(b), F.A.C.]	<input checked="" type="checkbox"/>	<input type="checkbox"/>
6	Secured radioactive storage and decay area. [64B16-28.901(4), F.A.C.]						<input checked="" type="checkbox"/>	<input type="checkbox"/>	21	Minimum equipment: fume hood with an air sampler, shielded radiation containment drawing station, dose calibrator, well scintillation counters, area rate meters, Geiger-Mueller (GM) survey meters, refrigerator, microscope, syringe shields, personnel radiation detection devices. [64B16-28.902(2), F.A.C.]	<input checked="" type="checkbox"/>	<input type="checkbox"/>
7	Compliance with all applicable laws and regulations of federal and state agencies for procurement, secure storage, inventory, preparation, distribution and disposal of radiopharmaceuticals. [64B16-28.901(5), F.A.C.]						<input checked="" type="checkbox"/>	<input type="checkbox"/>	22	Minimum supplies: syringes and vials, disposable gloves and protective lab coats, appropriate supplies to perform thin layer chromatography, lead transport shields for syringes and vials, DOT type 7A transport containers for shipping radioactive materials. [64B16-28.902(3), F.A.C.]	<input checked="" type="checkbox"/>	<input type="checkbox"/>
8	Pharmacy technicians may only receive diagnostic orders. [64B16-27.420(3), F.A.C.]						<input checked="" type="checkbox"/>	<input type="checkbox"/>	23	CQI Policy and Procedures and proof of quarterly meetings protected under [766.101, F.S.] [64B16-27.300, F.A.C.]	<input checked="" type="checkbox"/>	<input type="checkbox"/>
9	All orders for a therapeutic or blood-product radiopharmaceutical contain the patient's name prior to dispensing and must be received by the pharmacist only. [64B16-27.420(3), F.A.C.] [64B16-28.901(8)(i), F.A.C.]						<input checked="" type="checkbox"/>	<input type="checkbox"/>	24	Minimum current references: [10 CFR - FL], [49 CFR - DOT] [USP/NF, USP - DI], [404, F.S.], [465, F.S.] [893, F.S.], [64B16, F.A.C.], [64E-5, F.A.C.], [64B16-28.902(4), F.A.C.]	<input checked="" type="checkbox"/>	<input type="checkbox"/>
10	All registered pharmacy technicians wear identification badge with name and "Registered Pharmacy Technician". [64B16-27.420(4), F.A.C.]						<input checked="" type="checkbox"/>	<input type="checkbox"/>	Remarks:			
11	Policy and procedure available showing utilization of pharmacy technician. [64B16-27.440, F.A.C.]						<input checked="" type="checkbox"/>	<input type="checkbox"/>				
12	Radiopharmaceuticals are distributed only upon a prescription from an authorized medical practitioner or his agent. [64B16-28.901(6), F.A.C.]						<input checked="" type="checkbox"/>	<input type="checkbox"/>				
13	Transfers of radioactive materials by nuclear pharmacist is in accordance with all applicable laws and regulations. [64B16-28.901(7), F.A.C.]						<input checked="" type="checkbox"/>	<input type="checkbox"/>				
14	Each prescription contains name of authorized user or agent, date of distribution, time of administration, name of procedure, name of radiopharmaceutical, dose or quantity, serial # assigned to the order, any special instructions and the initials of the person who received the order. [64B16-28.901(8), F.A.C.]						<input checked="" type="checkbox"/>	<input type="checkbox"/>				
15	Oral prescriptions for radiopharmaceuticals are immediately reduced to writing. [64B16-28.901(8), F.A.C.]						<input checked="" type="checkbox"/>	<input type="checkbox"/>				

I have read and have had this inspection report and the laws and regulations concerned herein explained, and do affirm that the information given herein is true and correct to the best of my knowledge. I have received a copy of the Licensee Bill of Rights.

PRINT NAME Arlinda Chai

Arlinda Chai

Institutional Representative
INV 365 Revised 06/12, 12/11, 03/11, 01/07, 06/02

12-05-2013
Date

[Signature]

Investigator/Sr. Pharmacist Signature

ID oi129



**STATE OF FLORIDA
DEPARTMENT OF HEALTH
INVESTIGATIVE SERVICES**



WWW.DOH.STATE.FL.US

Standards of Practice for Compounding Sterile Preparations (CSPs)

ROUTINE CHANGE LOG NEW CURRENTLY NOT OPERATING CHANGE OWNER

File # 6825

Insp # 123200

INSPECTION AUTHORITY - CHAPTER 465.017, CHAPTER 893.09 AND CHAPTER 456, FLORIDA STATUTES

NAME OF ESTABLISHMENT ANAZAOHEALTH CORP		PERMIT NUMBER 16308	DATE OF INSPECTION 12/5/2013
DOING BUSINESS AS		DEA NUMBER	PRESCRIPTION DEPARTMENT MANAGER
STREET ADDRESS 5710 HOOVER BLVD		TELEPHONE # (813) 882-4500	EXT. ARLINDA OANH CHAI
CITY TAMPA	COUNTY 39	STATE/ZIP 33634	PRESCRIPTION DEPARTMENT MANAGER LICENSE # 399
COMPOUNDING PERSONNEL	MEDIA FILLED TEST DATE	COMPOUNDING PERSONNEL	MEDIA FILLED TEST DATE
See attached			
			SATISFACTORY N/A YES NO

High-Risk Level CSPs

- | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| 1 Sterilized high-risk preparations pass sterility test OR preparations are properly stored, prior to administration, not exceeding time periods specified in rule. [64B16-27.797(1)(o)4.] | <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> |
| 2 Personnel authorized to compound high-risk-level CSPs completed a media-filled test with high-risk test kit within the past 6 months (semiannually). [64B16-27.797(1)(i), F.A.C.] | <input checked="" type="checkbox"/> |
| 3 High risk sterile compounded preparations greater than 25 units have antimicrobial testing prior to dispensing [64B16-27.797(7)(a)3., F.A.C.] | <input checked="" type="checkbox"/> |

Medium and Low-Risk Level CSPs

- | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| 4 Medium-risk and low-risk preparations must pass sterility testing OR preparations are properly stored and do not exceed time periods specified in rule. [64B16-27.797(1)(n)4.; (o)4.] | <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> |
| 5 Personnel authorized to compound medium or low-risk level CSPs completed a media-filled test with medium-risk test kit within the past 12 months. [64B16-27.797(1)(n), F.A.C.] | <input checked="" type="checkbox"/> |

Barrier Isolator or Compounding Environment

- | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|
| 6 All sterile compounds prepared in barrier isolator which has been certified as ISO 5 by independent contractor. [64B16-27.797(5)(e), F.A.C.] | <input checked="" type="checkbox"/> |
| 7 Compounding environment appropriate for Risk Level (certification by independent qualified organization). Semi-annually for high risk, annual for medium and low-risk. | <input checked="" type="checkbox"/> |
| a) Anteroom/Ante area maintained within ISO class 8 [64B16-27.797(1)(a), F.A.C.] | <input checked="" type="checkbox"/> |
| b) Buffer area (clean room) maintained within ISO class 7 (separate room required for high-risk) [64B16-27.797(1)(f); (5)(a), F.A.C.] | <input checked="" type="checkbox"/> |
| c) Laminar Air Flow Hood(s) or class100 ISO room maintained within ISO class 5 [64B16-27.797(1)(k), F.A.C.] | <input checked="" type="checkbox"/> |
| 8 Buffer area does not contain sinks and drains. [64B16-27.797(1)(f), F.A.C.] | <input checked="" type="checkbox"/> |

Antineoplastic Drugs (Cytotoxins)

- | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|
| 9 Spill kits for antineoplastic agent spills. [64B16-27.797(5), F.A.C.] | <input checked="" type="checkbox"/> |
| 10 All cytotoxic preparations are compounded in a vertical flow, Class II, biological safety cabinet in a negative pressure room. [64B16-27.797(6), F.A.C.] | <input checked="" type="checkbox"/> |
| 11 Disposal of antineoplastic waste meets all applicable requirements. [64B16-27.797(6), F.A.C.] | <input checked="" type="checkbox"/> |

General Requirements

- | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|
| 12 P & P includes use of single/multidose containers not to exceed 797 guidelines. [64B16-27.797(4), F.A.C.] | <input checked="" type="checkbox"/> |
| 13 P & P includes verification of compounding accuracy and sterility. [64B16-27.797(4), F.A.C.] | <input checked="" type="checkbox"/> |
| 14 P & P includes personnel training and evaluation in aseptic manipulation skills. [64B16-27.797(4), F.A.C.] | <input checked="" type="checkbox"/> |
| 15 P & P includes environmental quality and control. [64B16-27.797(4), F.A.C.] | <input checked="" type="checkbox"/> |
| 16 Current reference material, hard copy or readily available online, are maintained. [64B16-27.797(5)(d), F.A.C.] | <input checked="" type="checkbox"/> |
| 17 Appropriate disposal containers. [64B16-27.797(5), F.A.C.] | <input checked="" type="checkbox"/> |
| 18 Appropriate temperature and transport devices. [64B16-27.797(5), F.A.C.] | <input checked="" type="checkbox"/> |
| 19 Adequate supplies (gloves, mask, etc.) to preserve a suitable environment for aseptic preparation and protective apparel for cytotoxins. [64B16-27.797(5)(6), F.A.C.] | <input checked="" type="checkbox"/> |
| 20 Documented on-going quality assurance program with audits at regular planned intervals. [64B16-27.797(7), F.A.C.] | <input checked="" type="checkbox"/> |
| 21 Compounding personnel skilled and trained based on observation. [64B16-27.797(7), F.A.C.] | <input checked="" type="checkbox"/> |
| 22 Compounding records properly maintained [64B16-28.140(4), F.A.C.] | <input checked="" type="checkbox"/> |
| 23 Quantity of compounded drug is reasonable considering the intended use and nature of the practitioner's practice [64B16-27.700(3)(b), F.A.C.] | <input checked="" type="checkbox"/> |

Remarks: Medrep certified anteroom, clean rooms and LAFWS 6-13 AND 6-14-2013

I have read and have had this inspection report and the laws and regulations concerned herein explained, and do affirm that the information given herein is true and correct to the best of my knowledge. I have received a copy of the Licensee Bill of Rights.

PRINT NAME OF RECIPIENT Arlinda Chai

Arlinda Chai

Institutional Representative
INV 797 Revised 12/12, 12/11 Created 8/11

12-05-2013
Date

[Signature]

Investigator/Sr. Pharmacist Signature

ID o1129